Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events.
He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been plagued with a myriad of troubling data suggesting that the technology is linked to thrombosis and target lesion failure.
Newly-developed scaffolds are only just beginning to live up to thin-strut metallic drug-eluting stents, Colombo told the audience at this year’s EuroPCR meeting.
“It’s a little bit sad that we went through mega-trials with devices that are so 1st generation when we almost have in our pocket a new-generation device,” the co-principal investigator said.